Prostate-specific antigen velocity is not better than total prostate-specific antigen in predicting prostate biopsy diagnosis

Gorday, William; Sadrzadeh, Hossein; Koning, Lawrence de; Naugler, Christopher

doi:10.1016/j.clinbiochem.2015.07.008

Cited by 3 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bittner et al 25 Prospective cohort 217 97 Biopsy findings PSAV did not predict PC diagnosis, Gleason score, percentage of positive cores, or tumor location. Gorday et al 26 Retrospective cohort 4622 2410 Biopsy findings PSAV with PSA AUC = 0.570-0.712 was non statistically significant compared to PSA alone (AUC = 0.572-0.699). Barak et al 27 Prospective cohort 273 75 Biopsy findings PSAV had slightly lower sensitivity but much higher specificity than PSA Fang et al 28 Prospective cohort 89 21 Biopsy findings The relative risk (RR) of CaP was 6.53 when the PSAV was 0.1 ng/ml/y or more compared with a PSAV of less than 0.1 ng/ml/y (P = 0.0029).…”

Section: The Diagnostic Value Of Prostate-specific Antigen Velocity In Detecting Prostate Cancermentioning

confidence: 96%

See 1 more Smart Citation

Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review

Javaeed¹,

Ghauri²,

Ibrahim³

et al. 2020

Oncol Rev

View full text Add to dashboard Cite

Prostate-specific antigen velocity (PSAV) is widely used to detect PC and predict its progression. In this study, we qualitatively synthesized the currently available evidence from published studies regarding the PSAV role in PC. Electronic databases were searched to find relevant articles published until January 2019. Inclusion and exclusion criteria were applied to identify related papers. Eventually, data extraction followed by evidence synthesis was conducted. Full-text screening resulted in 42 included studies. Multiple definitions and intervals were used for PSAV calculation across studies. Results from the included studies were conflicting regarding the role of PSAV in detecting PC and predicting progression in active surveillance cases. However, there is evidence that PSAV may have a predictive role in post-treated men. There is no clear-cut evidence from the published literature to support the use of PSAV in clinical practice.

show abstract

Section: The Diagnostic Value Of Prostate-specific Antigen Velocity In Detecting Prostate Cancermentioning

confidence: 96%

“…The PSAV was not showed to be a predictor for PC diagnosis, Gleason score, tumor volume, and cancer location. Gorday et al 26 included 4622 men. PSAV with PSA AUC = 0.570-0.712 was nonstatistically significant compared to PSA alone (AUC = 0.572-0.699).…”

Section: Reviewmentioning

confidence: 99%

Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review

Javaeed¹,

Ghauri²,

Ibrahim³

et al. 2020

Oncol Rev

View full text Add to dashboard Cite

show abstract

“…Initially, owing to low availability, MRI diagnosis may be better offered by specialized clinicians and cancer centres to appropriately triage patients who would benefit most from MRI and targeted biopsy (PI-RADS stage [4][5]. Performing tests at highvolume centres would accelerate learning and optimize reliability of test interpretation.…”

Section: Key Pointsmentioning

confidence: 99%

“…4 However, caution is warranted before considering changing guidelines and health care services. The aforementioned studies included men with higher prostate-specific antigen (PSA) levels (6.8-7.1 ng/mL), and therefore higher pretest probability of cancer, than those in men in contemporary Canadian biopsy cohorts, 5 which impairs generalizability of the findings. This effect is evident when reviewing the higher rates of detection of clinically important cancer observed in the PRECISION trial versus those at a tertiary Canadian centre (12%/60%/83% v. 6%/33%/64% for stage 3 [intermediate risk], 4 [high risk] and 5 [very high risk] lesions, respectively, using Prostate Imaging-Reporting and Data System [PI-RADS] version 2).…”

mentioning

confidence: 99%

Magnetic resonance imaging diagnosis of prostate cancer: promise and caution

Cheung

Finelli

2019

CMAJ

View full text Add to dashboard Cite

Preliminary clinical practice of radical prostatectomy without preoperative biopsy

Liu,

Yin,

et al. 2024

Chinese Medical Journal

View full text Add to dashboard Cite

Background: At present, biopsy is essential for the diagnosis of prostate cancer (PCa) before radical prostatectomy (RP). However, with the development of prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and multiparametric magnetic resonance imaging (mpMRI), it might be feasible to avoid biopsy before RP. Herein, we aimed to explore the feasibility of avoiding biopsy before RP in patients highly suspected of having PCa after assessment of PSMA PET/CT and mpMRI. Methods: Between December 2017 and April 2022, 56 patients with maximum standardized uptake value (SUVmax) of ≥4 and Prostate Imaging Reporting and Data System (PI-RADS) ≥4 lesions who received RP without preoperative biopsy were enrolled from two tertiary hospitals. The consistency between clinical and pathological diagnoses was evaluated. Preoperative characteristics were compared among patients with different pathological types, T stages, International Society of Urological Pathology (ISUP) grades, and European Association of Urology (EAU) risk groups. Results: Fifty-five (98%) patients were confirmed with PCa by pathology, including 49 (89%) with clinically significant prostate cancer (csPCa, defined as ISUP grade ≥2 malignancy). One patient was diagnosed with high-grade prostatic intraepithelial neoplasia (HGPIN). CsPCa patients, compared with clinically insignificant prostate cancer (cisPCa) and HGPIN patients, were associated with a higher level of prostate-specific antigen (22.9 ng/mL vs. 10.0 ng/mL, P = 0.032), a lower median prostate volume (32.2 mL vs. 65.0 mL, P = 0.001), and a higher median SUVmax (13.3 vs. 5.6, P <0.001). Conclusions: It might be feasible to avoid biopsy before RP for patients with a high probability of PCa based on PSMA PET/CT and mpMRI. However, the diagnostic efficacy of csPCa with PI-RADS ≥4 and SUVmax of ≥4 is inadequate for performing a procedure such as RP. Further prospective multicenter studies with larger sample sizes are necessary to confirm our perspectives and establish predictive models with PSMA PET/CT and mpMRI.

show abstract

Prostate-specific antigen velocity is not better than total prostate-specific antigen in predicting prostate biopsy diagnosis

Cited by 3 publications

References 30 publications

Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review

Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review

Magnetic resonance imaging diagnosis of prostate cancer: promise and caution

Preliminary clinical practice of radical prostatectomy without preoperative biopsy

Contact Info

Product

Resources

About